Brought to you by 
GSK licenses US nonprescription rights to Roche's orlistat
10 Sep 2004
Executive Summary
In exchange for SEK120mm ($100mm), GlaxoSmithKline Consumer Healthcare licensed the US rights from Roche to sell the obesity drug orlistat over the counter. Roche, which also stands to get milestones and royalties from the deal, currently sells orlistat as a prescription product under the brandname Xenical.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK licenses US nonprescription rights to Roche's orlistat
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice